Rather than evaluating each company in isolation, RA Capital organizes scientific and competitive information across therapeutic areas. A biotechnology company developing an Alzheimer's treatment, for example, must be assessed against every competing therapeutic mechanism, trial stage, target profile and likely future standard of care.
This type of structured research can provide a meaningful advantage because biotechnology markets are not static. A drug that looks commercially attractive today may lose much of its expected value when another company publishes superior data six months later.
TechAtlas is designed to give investment teams a broader map of each scientific field and help identify both companies worth investing in and areas where a new company should potentially be created.
That second function is important. RA Capital is not simply using research to select stocks. It increasingly uses research to identify scientific gaps and form new companies around them.
RAVEN AND COMPANY CREATION: FROM INVESTOR TO BIOTECH FOUNDER
RA Capital's Raven platform adds a venture-building dimension that differentiates the organization from most public-market hedge funds. The firm says Raven has helped originate, co-create and unlock value in dozens of healthcare companies since 2018.
The model begins before a conventional financing round. RA Capital can identify a scientific opportunity, recruit founders or executives, secure intellectual property, construct an initial development strategy and provide seed capital.
This creates potential advantages. The investor may enter at a much lower valuation than in a Series B or public-market financing and can help shape company strategy from inception.
It also creates conflicts and complexity. If RA Capital forms a company and later invests additional fund capital into it, valuation and allocation decisions must be handled carefully. The same manager can occupy multiple roles: founder, early investor, board member, later-round investor and public shareholder.
Investors should therefore understand how RA Capital prices internally incubated companies, how investment opportunities are allocated among Healthcare Fund, Nexus venture funds and other vehicles, and whether independent third-party investors participate in subsequent financing rounds.
The manager reports more than 30 companies created across its platform. That statistic provides evidence that incubation has become a material strategy rather than a side activity.
RA CAPITAL NEXUS: DEDICATED PRIVATE-MARKET CAPITAL
RA Capital's Nexus fund family provides another major layer of the platform.
Nexus vehicles are designed primarily for private biotechnology and healthcare investments. Public Form D records show successive generations including RA Capital Nexus Fund, Nexus II, Nexus III and Nexus IV, together with parallel international vehicles.
Nexus III became particularly large. Public offering data associated with the vehicle reported approximately $881 million sold. Earlier Nexus offerings also raised hundreds of millions of dollars.
The newest Nexus IV generation was filed in 2025.
This means RA Capital can finance companies at multiple points using different pools of capital. A newly formed company may receive investment through a venture fund, later receive crossover financing from one or more RA vehicles, and eventually appear in Healthcare Fund public holdings after an IPO.
The strategy can create continuity. RA Capital may know a business for years before it becomes public and can continue financing it through difficult capital-market cycles.
The same structure creates allocation questions. Investors in Healthcare Fund need to understand when a private opportunity belongs in Healthcare Fund versus Nexus, whether one vehicle receives more favorable entry terms, and how co-investments are split among affiliated funds.
These are normal institutional conflicts for a multi-fund venture/public platform but should be explicitly managed.
PUBLIC AND PRIVATE MARKETS: WHY RA CAPITAL IS A CROSSOVER INVESTOR
RA Capital's most important structural distinction is the ability to invest across the entire lifecycle of a life-sciences company.
Traditional venture capital firms often exit or reduce exposure shortly after IPO.
Traditional public-market hedge funds often begin investing only after shares are listed.
RA Capital operates across both.
A company may first enter the portfolio in a private financing, complete an IPO, issue additional public shares and remain an RA Capital holding for years afterward.
This approach can provide information continuity. Analysts who studied the science before a company went public do not need to rediscover the story after listing.
It also exposes the fund to very different liquidity conditions.
Private securities can be locked up for years.
Newly public biotechnology shares can be highly volatile and thinly traded.
Later-stage public companies may offer greater liquidity but still react dramatically to clinical data.
The fund therefore needs liquidity management across assets that behave very differently.
PUBLIC SEC OWNERSHIP: GERON, SOLID BIOSCIENCES, ACUMEN, VOR BIOPHARMA AND ARTIVA
RA Capital's investment activity is unusually easy to verify because the manager repeatedly appears in SEC beneficial-ownership filings.
In 2026, RA Capital filed an amended Schedule 13G relating to Geron Corporation, providing direct evidence of a significant ownership position.
Schedule 13D filings also show substantial positions in companies including Vor Biopharma, Solid Biosciences and Acumen Pharmaceuticals.
These are not passive marketing claims. A Schedule 13D generally becomes relevant when ownership reaches significant thresholds and the reporting person is not relying on passive-investor treatment.
RA Capital and the Healthcare Fund also appear in Section 16 Form 3 and Form 4 filings for numerous biotechnology companies.
Artiva Biotherapeutics is a particularly current example. A September 2026 Form 4 identifies RA Capital Management as both a director-related reporting person and 10% owner. The filing records an additional director stock option and demonstrates that RA Capital's involvement can extend beyond passive shareholding to board-level influence.
The portfolio spans different scientific areas:
Geron focuses on blood cancers and telomerase biology.
Solid Biosciences develops genetic medicines, including programs for neuromuscular and cardiac disease.
Acumen Pharmaceuticals develops therapies targeting Alzheimer's disease biology.
Vor Biopharma has operated in engineered hematopoietic stem-cell and oncology-related areas and has undergone significant strategic change.
Artiva develops cell-based therapies.
The diversity across therapeutic modality reduces dependence on one specific scientific technology but does not eliminate biotechnology sector risk.
FREENOME AND THE PRIVATE-TO-PUBLIC PIPELINE
Freenome provides a useful 2026 example of RA Capital's private-to-public investment model.
SEC filings from July 2026 identify RA Capital Healthcare Fund as a significant beneficial owner when Freenome became publicly reportable, with one filing showing 750,000 common shares in the initial ownership statement.
Freenome develops blood-based cancer detection technology.
Diagnostics companies differ substantially from drug developers. Their success depends not only on analytical accuracy but also on prospective clinical validation, reimbursement, physician adoption, screening guidelines and the economics of testing large populations.
RA Capital's ability to invest in both diagnostics and therapeutics demonstrates the breadth of the healthcare mandate.
But it also means analysts must master very different regulatory and commercialization frameworks. An oncology drug, medical device and diagnostic test can all produce healthcare innovation while having almost nothing in common financially.
PORTFOLIO SCALE: 250+ COMPANIES, 125+ IPOS AND 65+ ACQUISITIONS
RA Capital's own portfolio database currently lists more than 250 companies spanning healthcare and planetary health.
Its platform statistics state:
65+ portfolio companies acquired since inception 125+ IPOs since inception 70+ approved drugs financed 30+ companies created
These figures are unusually significant because they describe a full ecosystem rather than a handful of isolated wins.
The acquisitions include numerous biotechnology transactions in which large pharmaceutical companies bought RA-backed developers to acquire promising drugs or platforms.
RA Capital's portfolio page, for example, identifies 89bio as acquired by Roche in September 2025.
M&A matters particularly in biotechnology because a successful drug program does not always need to reach independent commercial scale. Large pharmaceutical companies frequently buy smaller companies after meaningful clinical de-risking.
This can produce exits before FDA approval and reduce the need for a small biotechnology business to build its own commercial infrastructure.
However, acquisition statistics alone do not establish fund performance. An investment sold for $2 billion can still produce an unattractive return if the company had already been valued near that level at entry.
The meaningful metrics are cost basis, ownership percentage, realized proceeds and net return after losses elsewhere in the portfolio.
BIOPHARMA M&A: "INSIDE THE ROOM WHERE IT HAPPENS"
RA Capital has also invested substantial research effort into understanding biotechnology acquisitions.
Its 2026 Semper Maior research focuses on biotech M&A and the decision process around strategic transactions.
This matters because acquisition probability is a major component of biotechnology valuation.
Large pharmaceutical companies face patent expirations and need to replace revenue through internal R&D, licensing and acquisitions.
Smaller biotechnology companies can become attractive targets when they have de-risked an asset but lack the global infrastructure to commercialize it efficiently.
RA Capital's broad portfolio and industry network can provide useful insight into what types of assets strategic buyers value.
Yet investors should avoid building an investment thesis around acquisition speculation alone.
A company can remain independent for years even when its science appears strategically attractive.
M&A premiums also shrink if the broader pharmaceutical industry becomes risk averse or if regulators apply greater antitrust scrutiny.
PLANETARY HEALTH: EXPANDING BEYOND BIOTECH
RA Capital expanded beyond traditional healthcare through RA Capital Planetary Health Fund.
The vehicle, formed in 2023, focuses on areas where biological science, climate, food, agriculture, materials and industrial technologies overlap.
Public Form D data associated with the domestic Planetary Health Fund showed approximately $122 million raised in its latest available amendment, while the related international vehicle reported roughly $30 million.
This strategy is distinct enough to deserve explanation but belongs to the same RA Capital brand and should not be treated as a separate manager for FilingDossier deduplication.
The intellectual link is biology.
Technologies originally developed for medicine—genetic engineering, fermentation, synthetic biology, computational biology and advanced manufacturing—can also be applied to food, chemicals, materials and agriculture.
RA Capital's July 2026 research on biomanufacturing specifically discussed where biological production can become commercially competitive.
Planetary Health broadens the opportunity set but also introduces industrial and commodity economics that differ from traditional drug development.
A therapeutics company can command extremely high margins if a drug works.
A biomanufacturing business may need to compete directly with inexpensive petrochemical or agricultural production.
Scientific success does not guarantee attractive industrial economics.
CHINA: SCIENTIFIC OPPORTUNITY VERSUS GEOPOLITICAL RISK
China has become an increasingly important part of global biotechnology development and a visible subject in RA Capital's 2026 research.
The firm published material in June 2026 discussing its work in China and in May argued against overly broad biotechnology protectionism.
The investment logic is straightforward. China has developed large pools of scientific talent, lower-cost clinical development capacity and increasingly competitive biotechnology companies.
Western pharmaceutical companies have also licensed Chinese-developed drugs at increasing rates.
For RA Capital, ignoring China could mean overlooking scientifically strong assets or partnership opportunities.
The risk is geopolitical.
U.S.-China biotechnology policy has become more restrictive, with legislators debating supply-chain dependence, data security, national security and relationships involving Chinese biotechnology service companies.
Trade restrictions, foreign-investment controls or sector-specific legislation can alter the value of cross-border biotechnology partnerships very quickly.
An investor therefore needs to understand RA Capital's China exposure not only through portfolio percentage but also through licensing agreements, contract research/manufacturing relationships and portfolio-company dependencies.
REGULATORY AUM VERSUS WEBSITE AUM: WHY THE TWO NUMBERS DIFFER
RA Capital's website reports more than $14.4 billion of assets under management as of December 31, 2025.
Its March 31, 2026 Form ADV-derived regulatory data reports approximately $16.4 billion of regulatory assets under management across 13 accounts.
Those numbers should not be portrayed as a contradiction.
Regulatory AUM follows SEC calculation rules and can include assets, leverage-related concepts and accounts differently from a manager's commercial AUM presentation.
The reporting dates also differ by three months.
The correct conclusion is that the platform operates at roughly mid-teens billions of dollars in current regulatory/manager-reported scale.
That makes RA Capital far larger than many specialist life-sciences venture firms.
Scale allows the organization to maintain large scientific research teams, company-building operations and capital for follow-on rounds.
It also creates capacity issues.
A $15+ billion specialist healthcare manager needs substantially larger investments to move firmwide returns than a $500 million boutique.
This may push the platform toward larger private rounds, public biotechnology companies and more diversified portfolios.
FORM 13F AND WHY IT SHOWS ONLY PART OF RA CAPITAL
RA Capital filed its June 30, 2026 Form 13F on August 14, 2026.
The filing confirms the institutional investment manager as RA Capital Management, L.P., CIK 0001346824, operating from the Boston headquarters.
13F is useful for identifying many U.S.-listed long positions but provides only a partial portfolio picture.
It does not show most private investments.
It does not reveal most short positions or many derivatives.
It can omit foreign securities and other instruments.
It is also backward-looking.
These limitations are especially important for RA Capital because private biotechnology investing and crossover financing are major parts of the strategy.
A researcher who evaluates RA Capital only through 13F holdings will miss a large portion of the actual investment platform.
Public Schedule 13D, 13G, Form 3 and Form 4 filings provide additional position-level detail when RA owns larger percentages or participates in boards.
COMPANY BOARDS AND GOVERNANCE INFLUENCE
RA Capital frequently takes board seats at portfolio companies.
This can improve access to governance and help companies recruit executives, plan financing and evaluate strategic alternatives.
It also creates fiduciary and information-management complexity.
A representative of RA Capital sitting on a public-company board can possess material nonpublic information, which may restrict trading by affiliated funds.
The manager therefore needs information barriers, restricted lists and compliance procedures governing portfolio-company securities.
The current Artiva filings illustrate this relationship: RA Capital appears as both a significant owner and director-related reporting person.
Board involvement can improve investment outcomes if the investor contributes scientific and strategic expertise.
But it can also increase reputational exposure when a portfolio company fails clinically, restructures or makes controversial decisions.
BIOTECH BINARY RISK: WHY SCIENTIFIC EXPERTISE DOES NOT REMOVE LARGE LOSSES
Biotechnology is one of the most binary areas of institutional investing.
A clinical-stage company may spend hundreds of millions of dollars developing one lead drug.
If a pivotal trial succeeds, market value can increase dramatically.
If it fails, the same company can lose most of its value in one trading session.
Diversification is therefore essential.
RA Capital's broad portfolio reduces dependence on any single drug program, but the sector can still experience correlated drawdowns when risk appetite falls.
Interest rates matter because many biotechnology companies generate no profits and must finance years of research before commercialization.
Higher rates increase the discount applied to future cash flows and can make equity financing expensive.
Clinical trial design also creates hidden risk.
A drug can show biological activity yet fail because the trial selects the wrong patients, uses an ineffective endpoint or is underpowered.
FDA standards can evolve.
Competitors can publish superior data before a company reaches approval.
Even approved products can disappoint if physicians do not adopt them or insurers restrict reimbursement.
CAPITAL INTENSITY AND FINANCING RISK
Many RA portfolio companies consume cash continuously.
A biotechnology company may require multiple financing rounds before generating commercial revenue.
This creates a dependence on capital markets that differs from profitable software or industrial businesses.
When biotech equity markets are strong, companies can raise hundreds of millions through follow-on offerings.
When markets close, the same companies may need to cut programs, lay off staff, pursue partnerships or sell themselves.
RA Capital's scale can be an advantage because it can participate in follow-on financings and help bridge companies through difficult periods.
But a manager cannot indefinitely finance every portfolio company.
Capital-allocation decisions become especially important when several holdings need new funding simultaneously.
Investors should understand how RA Capital decides whether to defend an existing investment, allow dilution or stop providing additional capital.
VALUATION RISK IN PRIVATE BIOTECH
Private biotechnology valuation can be highly subjective.
A company may raise a Series B at $500 million based largely on preclinical data.
If the public biotech market declines before the company's next financing, the realistic secondary value may be much lower even though no formal down round has occurred.
Managers must therefore decide how aggressively to mark private positions between financing events.
The existence of independent fund audits can provide procedural oversight but does not transform an illiquid private investment into an objectively quoted asset.
Investors should understand RA Capital's valuation policy, use of third-party pricing inputs and procedures for companies facing negative scientific developments before the next financing.
This issue becomes particularly important in crossover strategies because the same company can move from private valuation methodology to daily public-market pricing after IPO.
A large markdown at IPO does not necessarily mean the underlying science deteriorated; it may reflect changing market risk appetite.
M&A AND IPO CYCLES
RA Capital's platform has historically benefited from both IPOs and pharmaceutical acquisitions.
Its own statistics of 125+ IPOs and 65+ acquisitions demonstrate significant exposure to both exit channels.
Neither is continuously available.
The biotechnology IPO market can effectively close for long periods.
When IPO activity slows, private companies stay private longer and require additional capital.
M&A can partially substitute for IPO liquidity, but pharmaceutical buyers remain selective.
Large acquirers typically prefer programs with meaningful clinical validation.
Early-stage companies without human proof-of-concept may therefore struggle to find buyers during weak markets.
Fund liquidity and returns depend partly on this cycle.
Healthcare Fund has public-market liquidity that a traditional VC fund lacks, while Nexus funds can remain locked into private assets longer.
Investors should therefore evaluate each vehicle separately rather than assuming RA Capital's overall acquisition record applies equally to every fund.
PETER KOLCHINSKY'S DRUG-PRICING AND POLICY PROFILE
Peter Kolchinsky is also unusually active in public policy debates around pharmaceutical economics.
He has written extensively about drug pricing, innovation incentives and the structure of the U.S. healthcare system.
This creates a broader intellectual footprint for RA Capital than most healthcare hedge funds.
Policy expertise is relevant because biotechnology valuation depends heavily on reimbursement.
A drug can receive FDA approval and still fail commercially if payers restrict coverage or pricing is insufficient to support expected revenue.
U.S. drug-pricing reforms, Medicare negotiation and political pressure therefore directly affect portfolio economics.
Kolchinsky's public-policy involvement may improve the firm's understanding of these issues, but investors should distinguish his policy arguments from objective forecasts about future legislation.
Healthcare policy remains politically contested and can change across administrations and Congresses.
REGULATORY STATUS AND NEGATIVE-EVIDENCE REVIEW
RA Capital Management has been SEC registered since 2012 and files a substantial range of federal regulatory reports, including Form ADV, Form 13F, N-PX, Schedules 13D and 13G and Section 16 ownership forms.
Its 2026 Form ADV identifies CRD 160174 and SEC file 801-73980.
The reviewed current primary sources did not surface a defining SEC fraud or investment-management enforcement action against RA Capital Management or Peter Kolchinsky comparable to major historical hedge-fund scandals.
That statement should be interpreted narrowly. Large investment advisers are subject to routine examinations, and private commercial disputes or confidential regulatory interactions may not appear in public enforcement databases.
The manager's more material observable risks are sector-specific rather than identity-related: clinical failure, valuation drawdowns, biotech financing cycles, regulatory change, portfolio-company governance and the possibility that scientific theses fail.
Individual portfolio companies can also face lawsuits, trial setbacks, FDA issues or shareholder claims. Those should not automatically be attributed to RA Capital itself merely because it invested or held a board seat.
PORTFOLIO COMPANY FAILURE IS PART OF THE MODEL
An important Google-friendly distinction is that a biotechnology investor should not be judged by whether every portfolio company succeeds.
Failure is structurally expected.
Some experimental drugs will fail.
Some startups will shut down.
Some public holdings will lose most of their value.
The relevant question is whether gains from successful drugs, IPOs and acquisitions exceed those losses across the complete portfolio.
RA Capital's publicly visible acquisitions and IPOs indicate a substantial number of positive outcomes, but external researchers do not have enough information to calculate the Healthcare Fund's complete net performance from public filings.
The $4.17 billion Form D sales figure is fundraising history, not return.
The $14.4 billion website AUM figure is scale, not return.
The 125+ IPO and 65+ acquisition figures are portfolio-event counts, not return.
Investors need audited fund performance, monthly returns, exposure reports and realized/unrealized attribution to judge investment quality.
SERVICE PROVIDERS AND OPERATIONAL DILIGENCE
RA Capital's Form ADV contains private-fund and service-provider information, but the identities and responsibilities of providers can differ across Healthcare Fund, international feeders, Nexus vehicles and Planetary Health funds.
Prospective investors should confirm the current administrator, auditor, prime brokers, custodians, legal counsel and tax advisers directly from current audited financial statements and offering documents.
Prime-broker relationships matter because the Healthcare Fund can invest in public securities and may use financing, derivatives or short exposure depending on mandate.
Custody and administration are particularly important when the manager holds both publicly traded and private securities.
Investors should also review cybersecurity and material-nonpublic-information procedures because RA Capital combines public trading with private company investing and board participation.
That combination creates operational complexity beyond a pure venture fund or pure public equity fund.
PLANETARY HEALTH, NEXUS AND HEALTHCARE FUND SHOULD NOT BE COUNTED AS THREE SEPARATE BRANDS
For FilingDossier's deduplication system, RA Capital should now be treated as one completed manager brand.
The following belong to the same broader platform:
RA Capital Management, L.P. RA Capital Healthcare Fund LP Former RA Capital Biotech Fund LP RA Capital Healthcare International Fund Ltd. RA Capital Nexus Fund RA Capital Nexus Fund II RA Capital Nexus Fund III RA Capital Nexus Fund IV Parallel Nexus International vehicles RA Capital Planetary Health Fund RA Capital Planetary Health International Fund Raven TechAtlas
The strategies are not identical, but the manager, research infrastructure, leadership and investment ecosystem substantially overlap.
Future sequential generation should skip those vehicles unless a specific fund is explicitly requested for a separate standalone analysis.
FINAL ASSESSMENT
RA Capital Healthcare Fund LP is a highly established healthcare investment vehicle with approximately two decades of private-offering history. The April 20, 2026 Form D amendment reports $4,170,818,373 cumulatively sold to 947 investors, an indefinite Rule 506(b) offering and Section 3(c)(7) status. Peter Kolchinsky signed the filing as a manager of the general partner, and the same SEC record preserves the earlier RA Capital Biotech Fund LP name.
The manager is substantially larger than the fund's cumulative Form D figure alone suggests. RA Capital's public website reports more than $14.4 billion of AUM as of December 31, 2025, while March 2026 Form ADV-derived regulatory data reports approximately $16.4 billion of regulatory AUM across 13 accounts. RA Capital Management is SEC registered under CRD 160174 / SEC 801-73980.
The platform is differentiated by scientific specialization and full-lifecycle investing. TechAtlas supports evidence-based research; Raven forms companies; Nexus funds provide private venture capital; Healthcare Fund can invest across private and public markets; and Planetary Health extends the model into biological and industrial technologies beyond traditional medicine.
Independent securities filings provide unusually strong evidence of actual portfolio activity. RA Capital appears in current ownership filings involving Geron, Solid Biosciences, Acumen Pharmaceuticals, Vor Biopharma, Artiva Biotherapeutics, Freenome and numerous other life-sciences issuers. Its involvement can include significant ownership, board seats and financing participation.
The firm's own portfolio statistics report more than 250 companies, 125+ IPOs, 65+ acquisitions, 70+ approved drugs financed and 30+ companies created. These metrics demonstrate operating scale but should not be confused with audited fund returns.
The largest investment risks arise directly from RA Capital's specialization. Clinical trial results can destroy value overnight. FDA decisions can change commercial prospects. Private biotech valuations are subjective. Public biotech markets periodically experience severe capital droughts. High interest rates increase financing pressure. China creates both scientific opportunity and geopolitical uncertainty. Board involvement and private-company access require strong information-control procedures.
RA Capital therefore has a very strong legitimacy and institutional identity profile, but that should not be translated into an assumption of low risk. Healthcare investing is inherently volatile even when performed by experienced scientists and investors.
A prospective LP should focus on audited net returns, historical maximum drawdown, private/public allocation, leverage, top-ten concentration, realized versus unrealized gains, valuation methodology, liquidity terms, Nexus-versus-Healthcare allocation rules, service providers and key-person provisions.
SEC SNAPSHOT
Issuer: RA Capital Healthcare Fund LP Previous Name: RA Capital Biotech Fund LP CIK: 0001315082 Entity Type: Limited Partnership Jurisdiction: Delaware Principal Address: 200 Berkeley Street, 18th Floor, Boston, MA 02116 Phone: 617-778-2500 Fund Type: Pooled Investment Fund / Hedge Fund First Sale Date: January 1, 2005 Latest Form D: Form D/A Latest Form D Date: April 20, 2026 Offering Duration: More Than One Year Offering Size: Indefinite Offering Exemption: Regulation D Rule 506(b) Investment Company Act Exclusion: Section 3(c)(7) Latest Total Amount Sold: $4,170,818,373 2025 Total Amount Sold: $4,020,194,043 2024 Total Amount Sold: $3,851,543,208 2026 Increase Versus Prior Filing: Approximately $150.62 million Latest Investors: 947 Regulatory Minimum Investment on Form D: $0 Sales Commissions: $0 Finder's Fees: $0 General Partner: RA Capital Healthcare Fund GP, LLC Latest Form D Signatory: Peter Kolchinsky Signatory Role: Manager of General Partner Investment Manager: RA Capital Management, L.P. Manager CIK: 0001346824 Manager CRD: 160174 Manager SEC File: 801-73980 SEC Registration Effective: March 30, 2012 Manager Headquarters: 200 Berkeley Street, 18th Floor, Boston, MA 02116 RA Capital Website AUM: $14.4B+ as of December 31, 2025 Latest Form ADV-Derived Regulatory AUM: Approximately $16.4B as of March 31, 2026 Latest Form ADV Client Accounts: 13 Public Website Portfolio Companies: 250+ Companies Acquired Since Inception: 65+ Portfolio IPOs Since Inception: 125+ Approved Drugs Financed: 70+ Companies Created: 30+ Managing Partner: Peter Kolchinsky, PhD Managing Partner / Portfolio Manager: Rajeev Shah Other Healthcare Partners Publicly Identified: Zach Scheiner, PhD; Jake Simson, PhD; Matt Hammond, PhD/MBA; Derek DiRocco, PhD; Josh Resnick, MD and additional scientific/investment professionals Primary Strategy: Healthcare / Life Sciences Investment Stages: Company Formation; Seed; Series A/B/C; Crossover; IPO; Follow-On Financing; Public Markets; Structured Capital Research Platform: TechAtlas Healthcare Company Formation Platform: Raven Raven Active Since: 2018 Dedicated Private Fund Family: RA Capital Nexus Representative Nexus Fund III Historical Raise: Approximately $881 million Newest Nexus Generation: Nexus Fund IV Adjacent Strategy: RA Capital Planetary Health Planetary Health Domestic Fund Latest Public Amount Sold: Approximately $122 million Planetary Health International Fund Latest Public Amount Sold: Approximately $30 million Representative Current / Historical Public Holdings: Geron; Solid Biosciences; Acumen Pharmaceuticals; Vor Biopharma; Artiva Biotherapeutics; Freenome and numerous other healthcare issuers Current 2026 SEC Ownership Evidence: Schedule 13D, Schedule 13G, Form 3 and Form 4 filings across multiple portfolio companies Current Form 13F Period: June 30, 2026 Form 13F Filed: August 14, 2026 Representative 2025 M&A Outcome: 89bio acquired by Roche Major Current Research Themes: Biotech M&A; drug value and reimbursement; China biotechnology; biomanufacturing; healthcare innovation China Exposure: Publicly acknowledged as an area of research and investment activity Complete Current Fund Portfolio: Not publicly disclosed Current Fund NAV: Not established by Form D cumulative sales Current Audited Net Return: Not publicly disclosed in Form D Current Gross / Net Leverage: Requires fund documents Current Fee Structure: Requires current PPM / LPA Current Administrator / Auditor / Prime Broker / Custodian: Requires confirmation from current fund documents Major Current Manager-Level SEC Enforcement Identified in Reviewed Primary Sources: No defining public fraud enforcement action identified; this does not establish absence of confidential exams or private disputes Primary Risks: Clinical trial failure, FDA and regulatory risk, binary event risk, patent and intellectual-property risk, reimbursement and drug-pricing policy, private-company valuation, biotech capital-market cycles, concentration, crossover liquidity, financing dilution, China/geopolitical exposure, information-barrier complexity and key-person risk Entity Confusion Warning: RA Capital Healthcare Fund LP is the renamed continuation of RA Capital Biotech Fund LP and should not be counted separately from the broader RA Capital Management platform. Duplicate Brand Rule: RA Capital Healthcare Fund, former RA Capital Biotech Fund, Healthcare International Fund, Nexus I-IV and parallel international vehicles, Planetary Health funds, Raven and TechAtlas belong to the same RA Capital platform and should not be generated again as separate FilingDossier brands unless specifically requested. Independent Conclusion: RA Capital Healthcare Fund LP has a highly verifiable institutional identity supported by more than 20 years of SEC private-offering history, an SEC-registered investment adviser, extensive public-company ownership filings, a large private and public healthcare portfolio, dedicated venture funds and company-building infrastructure. The manager's scientific expertise and full-lifecycle platform are substantial differentiators, but biotechnology remains a high-volatility investment category in which clinical, regulatory and financing failures can generate severe losses. The most important unresolved questions concern current net performance, private/public allocation, leverage, liquidity, valuation and affiliated-fund allocation rather than whether the RA Capital organization or Healthcare Fund genuinely exists.
Independent research summary based on SEC Form D, Form ADV, Form 13F, Schedules 13D/13G, Section 16 filings, RA Capital first-party portfolio/team disclosures and other public regulatory materials. Form D, SEC adviser registration, board participation and portfolio-company regulatory filings are not SEC approval, verification of investment performance or guarantees of investment returns.